

With enthusiasm, looking for new ways



Dr. Antonello Arrighi,
Paediatric outpatients' dpt., Arezzo, Italy

Antonello Arrighi se v rozhovoru zmiňuje o své pediatrické praxi, v které užívá i přípravky fyziologické regulační medicíny (FRM, medicíny nízkých dávek). Informuje o řadě seminářů, které organizoval v Itálii ve spolupráci s Italskou společností pro preventivní a sociální pediatrii (SIPPS) s cílem, aby se s medicínou nízkých dávek více obeznámili italská pediatrii. Upozorňuje na rostoucí zájem o tuto léčbu mezi italskými pacienty i lékaři. Používání FRM představuje optimální doplněk oficiální klasické medicíny.

Jak upozorňuje dr. Arrighi, v časopise *La Medicina Biologica* vyjde v listopadu 2013 článek, v kterém budou zveřejněny výsledky klinické studie, v níž je srovnávána účinnost imunomodulačního přípravku Gunaprevac v léčbě chřipky a chřipkovitých onemocnění s paracetamolem. V této studii je poprvé zkoumána účinnost Gunaprevacu nejen v prevenci, ale v léčbě příznaků těchto onemocnění. Výsledky ukázaly, že je účinnější než paracetamol. Navíc paracetamol musí být užíván s opatrností, neboť zvyšuje riziko vzniku nebo zhoršení astmatu. Dr. Arrighi zdůrazňuje, že používání přípravku Gunaprevac, obdobně jako ostatních přípravků medicíny nízkých dávek, není spojeno s nežádoucími účinky.

1. Doctor, tell us, what interesting happened in your pediatric practice after our last interview last year?

In Italy, along with the AIOT we realized a series of refresher seminars in collaboration with the SIPPS, Italian Society of Preventive and Social Paediatrics, to make the Low Dose Medicine known to all the Paediatricians. I'm glad that after years during which we, doctors of non-conventional medicine, worked and sowed so much that now we are collecting the fruits, being granted access with full rights to the universities and the accredited societies. I notice a continuously increasing interest on the part of patients and medical colleagues concerning low dose medicine, which offers itself as a supplement to official medicine, in the unique interest of the health of children. My seminars, which already began in September, concern the whole Italian territory, and were met with great success on the part of the audience and the critics.

2. Summer is over, approaching days with inclement weather, falling leaves and mists. Do you expect increasing number of clients? How do you prepare yourself for the season of autumn and winter actually?

Surely, respiratory diseases are going to increase during the autumn and winter, but the preventive measures that I put to use, with

With enthusiasm, looking for new ways

Antonello Arrighi in the interview refers to his pediatric practice and his use of physiological regulative medicine (PRM) and inform about series of seminars he organized in collaboration with the SIPPS, Italian Society of Preventive and Social Paediatrics, to make PRM (or, in another words, Low Dose Medicine) known to italian paediatricians. He notice continuously increasing interest on the part of patients and doctors concerning PRM, which offers itself as a supplement to official classic medicine.

As dr. Arrighi points out, during november 2013 in journal *La Medicina Biologica* will be published results of clinical trial examining efficacy of Gunaprevac (PRM immunomodulator) compared with paracetamol for therapy of flu and flu-like illnesses (ILI). In this study, the first of its kind, Gunaprevac was tested not only for prevention, but for treatment of flu symptoms and proved be more efficient than paracetamol. Moreover, paracetamol must be used with caution, because it exposes the patients to the risk of onset or aggravation of the asthma. Arrighi emphasize that use of Gunaprevac, like other low dose drugs, proves to be free of adverse events.



draining remedies, like Guna Lympho and Guna Matrix, during summer and the immunomodulatory drugs, like Citomix and Gunaprevac, will make my job easier and will help young patients to maintain their state of health. I have been implementing these preventive measures for several years already and the very positive results obtained encourage me to expand such therapy on a large scale.

3. The magazine La Medicina Biologica in November will publish clinical trial results of Gunaprevac's efficacy compared with paracetamol for flu and flu- like illness (ILI). You can acquaint us with the methodology and design of this study?

In this study, the first of its kind, Gunaprevac is tested not for prevention, but for the treatment of flu symptoms. Till now it was said that Gunaprevac was efficient in preventing ILI, Up to now, it has been said that such remedy is also efficient in the treatment of the febrile symptoms, better than Paracetamol and also concerning the general, respiratory and gastrointestinal symptoms. The resolution implemented by Gunaprevac is faster, and more durable and stable with respect to the classic Paracetamol. Furthermore, there is a lower use of antibiotics in the low dose group, which also means a saving in terms of healthcare costs.

4. The results confirmed not only very good efficiency of Gunaprevacu symptomatic with fever, myalgia, dry cough, headache, catarrh of the mucous membranes and respiratory tract, but also anti-inflammatory effect. In contrast, acetaminophen does not have anti-inflammatory effects and analgesic and antipyretic properties are limited dose. Would you recommend therefore to your colleagues pediatricians – Gunaprevac or paracetamol?

Now, with no doubt, in the light of what was experienced, I advise all my colleagues and the families of my little patients to use Gunaprevac because it's more efficient and free of side effects.

5. Paracetamol has recently mentioned the increased risk of asthma when administered to children. What is the opinion on this issue in Italy?

Without a doubt, in patients with asthma, we know from the test of time that Paracetamol has to be used with caution, because it exposes the patients to the risk of onset or aggravation of the asthma. While the use of Gunaprevac, like other low dose drugs, proves to be free of adverse events.

interviewed by PharmDr. Lucie Kotlarova